Research programme: small molecule therapeutics - OXIS International

Drug Profile

Research programme: small molecule therapeutics - OXIS International

Alternative Names: OXS 4135; OXS 4235; p62-zz inhibitors - OXIS International

Latest Information Update: 06 Aug 2015

Price : $50

At a glance

  • Originator ID4 Pharma
  • Developer ID4 Pharma; OXIS International
  • Class Small molecules
  • Mechanism of Action NF-kappa B inhibitors; P38 mitogen-activated protein kinase inhibitors; SQSTM1 protein inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma; Osteolysis

Most Recent Events

  • 04 Aug 2015 Oxis Biotech executes amended option agreement with the University of Pittsburgh
  • 04 Jun 2015 Preclinical trials in Osteolysis in USA (Parenteral)
  • 04 Jun 2015 Preclinical trials in Multiple myeloma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top